|Awarded On||August 17, 2022|
|Title||Development of DKK3-Targeted Therapeutic Antibodies for Cancer|
|Program||Product Development Research|
|Award Mechanism||Seed Awards for Product Development Research|
|Institution/Organization||Stellanova Therapeutics, Inc.|
|Principal Investigator/Program Director||Richard Jones|
|Cancer Sites||Bladder, Breast, Pancreas|
Novel therapies are urgently needed for pancreatic cancer (PDAC) and triple negative breast cancer (TNBC), two of the most aggressive cancers with no effective cure. For PDAC, 4420 Texans and 60,000 Americans are diagnosed each year and only 7% are expected to survive 5 years. TNBC is also aggressive, affecting 3000 women in Texas and 42,000 in the US annually, with a disproportionate impact on African American and Hispanic women. Stellanova's co-founders have demonstrated that cells in the tumor microenvironment of PDAC and TNBC produce Dickkopf-3 (DKK3) that acts on neighboring cancer cells to stimulate their growth, metastasis and resistance to standard therapy. We have developed novel an...